CURE spoke with Dr. Marina Kremyanskaya about the treatment landscape for patients with polycythemia vera.

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients ...

Treatments with therapeutic phlebotomy and hydroxyurea are associated with improved overall survival and decreased risk of thrombosis in older patients with polycythemia vera, according to a recent ...

Of the 18 PV patients treated with PTG-300, the vast majority were able to eliminate therapeutic phlebotomies and maintain a target hematocrit level of less than 45 percent. Treatment with PTG-300 was ...

Evaluation in 18 patients with polycythemia vera showed hematocrit control below 45%, accompanied by a "dramatic decrease in ...

CHARLESTON, S.C.--(BUSINESS WIRE)--The Blood Connection (TBC), your community blood center, is proud to serve the Charleston community through free therapeutic phlebotomy. This service is free for ...

PARKVILLE, Mo.--(BUSINESS WIRE)--Bond Biosciences, Inc. “We are pleased to begin this first-in-human clinical trial of our lead non-absorbed oral therapy and thankful for the seasoned development team ...

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced details from a poster presentation with final data from the rusfertide Phase 2 REVIVE study. Rusfertide, a mimetic of the ...